Hongbo Medicine: This year, the company sorted out the commercial production sector and formulated a new 2+N development strategy.

Express information hot topic


According to the news of Securities Star,Express information Hongbo Pharmaceutical (301230) answered investors' concerns on the investor relations platform on November 29th.

Investors:Does the company plan to establish its own DEL library of compounds? Which company's DEL library is used for high-throughput screening at present? thank you

Hongbo Pharmaceutical Secretary-General:Dear investors, hello! The company adopts the method of artificial intelligence (AI)/ machine learning (ML), which can complete the virtual screening of hundreds of millions of molecules in a few days. Thanks for your attention!

Investors:I would like to ask which injection and oral pharmaceutical companies have been associated with oxiracetam, the raw material currently used by the company to treat Alzheimer's disease? When is the API expected to contribute to the performance? thank you

Hongbo Pharmaceutical Secretary-General:Dear investors, hello! This year, the company sorted out the commercial production sector and formulated a new 2+N development strategy. Thanks for your attention!

Investors:Baicheng Pharmaceutical is also engaged in CRO and CDMO, and it also has its own research and transfer business. Excuse me, does Hongbo Pharmaceutical also have self-research and transfer business? How many varieties are developed by ourselves at present? thank you

Hongbo Pharmaceutical Secretary-General:Dear investors, hello! The company's self-research projects mainly focus on the research and development of cutting-edge technology reserves and innovative drug production processes. Thanks for your attention!

Investors:According to the semi-annual report, the number of R&D employees of Hongbo Pharmaceutical is about 20% more than that of Baicheng Pharmaceutical. How much will the number of R&D employees increase by the end of the year? thank you

Hongbo Pharmaceutical Secretary-General:Dear investors, hello! Please pay attention to the company's periodic reports on the number and composition of employees. Thanks for your attention!

Investors:I would like to ask whether the shareholders who recently lifted the ban are still increasing their holdings because their share prices are too low. Which shareholders are increasing their holdings? thank you

Hongbo Pharmaceutical Secretary-General:Dear investors, hello! Please pay attention to the company announcement for relevant information. thank you

The above contents are compiled by Securities Star according to public information and generated by algorithm, which has nothing to do with the position of this website. Securities Star strives for but does not guarantee the accuracy, completeness, effectiveness and timeliness of all or part of this information (including but not limited to text, video, audio, data and charts). Please contact us if you have any questions. This article is for data collation, and does not constitute any investment advice for you. Investment is risky, so please make a careful decision.

转载请注明:http://www.daiyunhj.net/post/20240212/94f299594.html

游客
发表我的评论 换个身份
取消评论

Hi,您需要填写昵称和邮箱!

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址